Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002131 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma
A Phase 2 study, sponsored by Otsuka America Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00002131: Completed Phase 2 study, sponsored by Otsuka America Pharmaceutical.
NCT00002131 is a Phase 2 study that has completed, run by Otsuka America Pharmaceutical. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002131, a Phase 2 study, has completed, sponsored by Otsuka America Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related Kaposi's sarcoma.
Interventions
- DRUG Vesnarinone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Phase | Phase 2 |
What the finished NCT00002131 record still lists
NCT00002131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which Vesnarinone is the first listed.
NCT00002131 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002131 about?
NCT00002131 is a clinical study titled "A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma". To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related Kaposi's sarcoma.
What is the current status of trial NCT00002131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants.
What interventions are being tested in trial NCT00002131?
The interventions under investigation include: Vesnarinone (DRUG).
Who is sponsoring clinical trial NCT00002131?
This trial is sponsored by Otsuka America Pharmaceutical, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002131's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors